CARDIFF ONCOLOGY INC's ticker is CRDF and the CUSIP is 14147L108. A total of 59 filers reported holding CARDIFF ONCOLOGY INC in Q3 2023. The put-call ratio across all filers is 0.28 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $26,410 | +14.3% | 19,000 | +20.9% | 0.00% | – |
| Q2 2023 | $23,098 | -93.1% | 15,713 | -92.3% | 0.00% | – |
| Q1 2023 | $336,349 | -14.4% | 203,848 | -27.4% | 0.00% | – |
| Q4 2022 | $393,072 | -32.2% | 280,766 | -25.5% | 0.00% | – |
| Q3 2022 | $580,000 | -27.5% | 376,736 | +3.6% | 0.00% | – |
| Q2 2022 | $800,000 | +52.7% | 363,719 | +72.0% | 0.00% | – |
| Q1 2022 | $524,000 | -84.2% | 211,454 | -61.6% | 0.00% | – |
| Q4 2021 | $3,311,000 | +360.5% | 550,974 | +409.7% | 0.00% | – |
| Q3 2021 | $719,000 | -76.9% | 108,100 | -76.9% | 0.00% | – |
| Q2 2021 | $3,109,000 | +1223.0% | 467,461 | +1741.2% | 0.00% | – |
| Q1 2021 | $235,000 | -24.9% | 25,389 | +46.2% | 0.00% | – |
| Q4 2020 | $313,000 | +89.7% | 17,371 | +49.5% | 0.00% | – |
| Q3 2020 | $165,000 | +35.2% | 11,620 | -52.3% | 0.00% | – |
| Q2 2020 | $122,000 | – | 24,339 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 2,522,083 | $16,797,000 | 13.61% |
| Octagon Capital Advisors LP | 982,753 | $6,545,000 | 1.61% |
| Altium Capital Management LP | 348,888 | $2,324,000 | 0.61% |
| ACT CAPITAL MANAGEMENT, LLC | 102,500 | $683,000 | 0.35% |
| Eventide Asset Management | 1,670,399 | $11,125,000 | 0.15% |
| Artal Group S.A. | 750,000 | $4,995,000 | 0.11% |
| Virtus ETF Advisers LLC | 25,770 | $172,000 | 0.08% |
| HighVista Strategies LLC | 15,501 | $103,000 | 0.07% |
| ELKHORN PARTNERS LIMITED PARTNERSHIP | 13,500 | $90,000 | 0.05% |
| SCHOLTZ & COMPANY, LLC | 16,625 | $111,000 | 0.04% |